Valuation: OPTHEA

Market Cap 16.42M 11.42M 9.99M 9.21M 8.51M 16.14M 1.09B 110M 43.22M 536M 42.87M 41.94M 1.84B P/E 2026 *
-
P/E 2027 * -
Enterprise Value -12.78M -8.89M -7.78M -7.17M -6.63M -12.57M -848M -85.72M -33.66M -418M -33.39M -32.66M -1.44B EV / Sales 2026 *
-
EV / Sales 2027 * -0.53x
Free-Float
74.06%
Yield 2026 *
-
Yield 2027 * -
1 day-97.73%
3 months-97.73%
6 months-97.73%
Current year-97.73%
Current year 0.01
Extreme 0.01
0.01
1 year 0.01
Extreme 0.01
0.01
3 years 0.01
Extreme 0.01
0.57
5 years 0.01
Extreme 0.01
0.82
10 years 0.01
Extreme 0.01
2.51
Manager TitleAgeSince
Chief Executive Officer 72 01/09/2025
Director of Finance/CFO - 27/10/2025
Chief Tech/Sci/R&D Officer - 08/04/2024
Director TitleAgeSince
Director/Board Member 47 24/07/2020
Chairman 72 05/10/2020
Director/Board Member 59 15/11/2024
Change 5-day change 1-year change 3-year change Capi.($)
-97.73%-.--% - - 12.35M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-2.93%+2.65%+18.45%+461.25% 25.63B
-1.47%-2.42%-19.54%-14.68% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-0.80%+1.98%+25.37%+196.96% 14.35B
Average -10.48%+1.16%+54.42%+147.26% 26.91B
Weighted average by Cap. -1.13%+0.29%+54.92%+137.51%

Financials

2026 *2027 *
Net sales - 1.1M 765K 669K 617K 570K 1.08M 72.97M 7.38M 2.9M 35.95M 2.87M 2.81M 124M
Net income 337M 234M 205M 189M 175M 331M 22.35B 2.26B 887M 11.01B 880M 861M 37.85B -12.6M -8.76M -7.67M -7.07M -6.53M -12.39M -836M -84.48M -33.18M -412M -32.91M -32.19M -1.42B
Net Debt -29.2M -20.31M -17.77M -16.39M -15.13M -28.72M -1.94B -196M -76.89M -954M -76.26M -74.6M -3.28B -17M -11.82M -10.34M -9.54M -8.81M -16.72M -1.13B -114M -44.76M -556M -44.4M -43.43M -1.91B
Logo OPTHEA
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. It is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. It has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. It is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.
Employees
33
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise